PTK2 and glioma: Further, AMPAR-dependent activation of FAK in glioma cells should be our next target of investigation [31]; 3) More importantly, therapeutic intervention was not much focused in the present study represented by the insufficient effect of pharmacological approaches to inhibit glutamate signaling alone (Fig. 6F), and potential therapeutic targets/nodes in this scenario should be identified with metabolism-based screening approaches [23].